Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease
Corresponding Author
Inger van Steenoven BSc
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Correspondence to: Inger van Steenoven; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden, E-mail: [email protected]Search for more papers by this authorDag Aarsland MD, PhD
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway
Department of Neurology, Akershus University Hospital, Oslo, Norway
Search for more papers by this authorHoward Hurtig MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorAlice Chen-Plotkin MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorJohn E. Duda MD
Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Search for more papers by this authorJacqueline Rick PhD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorLama M. Chahine MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorNabila Dahodwala MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorJohn Q. Trojanowski MD, PhD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorDavid R. Roalf PhD
Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorPaul J. Moberg PhD
Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorDaniel Weintraub MD
Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Department of Psychiatry, Geriatric Psychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorCorresponding Author
Inger van Steenoven BSc
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Correspondence to: Inger van Steenoven; Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden, E-mail: [email protected]Search for more papers by this authorDag Aarsland MD, PhD
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway
Department of Neurology, Akershus University Hospital, Oslo, Norway
Search for more papers by this authorHoward Hurtig MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorAlice Chen-Plotkin MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorJohn E. Duda MD
Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Search for more papers by this authorJacqueline Rick PhD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorLama M. Chahine MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorNabila Dahodwala MD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorJohn Q. Trojanowski MD, PhD
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorDavid R. Roalf PhD
Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorPaul J. Moberg PhD
Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorDaniel Weintraub MD
Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
Department of Psychiatry, Geriatric Psychiatry Section, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Search for more papers by this authorFunding agencies: No financial support was received for this work.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Author roles may be found in the online version of this article.
ABSTRACT
Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). Thus, routine screening of global cognitive abilities is important for the optimal management of PD patients. Few global cognitive screening instruments have been developed for or validated in PD patients. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Dementia Rating Scale-2 (DRS-2) have been used extensively for cognitive screening in both clinical and research settings. Determining how to convert the scores between instruments would facilitate the longitudinal assessment of cognition in clinical settings and the comparison and synthesis of cognitive data in multicenter and longitudinal cohort studies. The primary aim of this study was to apply a simple and reliable algorithm for the conversion of MoCA to MMSE scores in PD patients. A secondary aim was to apply this algorithm for the conversion of DRS-2 to both MMSE and MoCA scores. The cognitive performance of a convenience sample of 360 patients with idiopathic PD was assessed by at least two of these cognitive screening instruments. We then developed conversion scores between the MMSE, MoCA, and DRS-2 using equipercentile equating and log-linear smoothing. The conversion score tables reported here enable direct and easy comparison of three routinely used cognitive screening assessments in PD patients. © 2014 International Parkinson and Movement Disorder Society
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site.
| Filename | Description |
|---|---|
| mds26062-sup-0001-suppfig1.tif18.4 MB | Supplemental Data Figure S1. Frequency plots of MMSE, MoCA and DRS-2. |
| mds26062-sup-0002-supptbl1.docx93.9 KB | Supplementary Table S1: Conversion table for possible DRS-2 score to MMSE score |
| mds26062-sup-0003-supptbl2.docx93.7 KB | Supplementary Table S2: Conversion table for possible DRS-2 score to MoCA score |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1996; 244: 2-8.
- 2 Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-2324.
- 3 Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders 2007; 22: 1689-1707.
- 4 Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-356.
- 5 Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011; 26: 629-636.
- 6 Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
- 7 Hely Ma, Reid WGJ, Adena Ma, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
- 8 Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-1069.
- 9 Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-1126.
- 10 Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009; 24: 1103-1110.
- 11 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
- 12 Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord 2008; 23: 297-299.
- 13
Wind AW,
Schellevis FG,
Van Staveren G,
Scholten RJ,
Jonker C,
Van Eijk JM. Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr Psychiatry 1997; 12: 101-108.
10.1002/(SICI)1099-1166(199701)12:1<101::AID-GPS469>3.0.CO;2-R CASPubMedWeb of Science®Google Scholar
- 14 Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 2003; 60: 1777-1781.
- 15 Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment–Revised (CAMCOG-R). Age Ageing 2005; 34: 268-273.
- 16 Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. J Neurol 2008; 255: 255-264.
- 17 Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
- 18 Nazem S, Siderowf AD, Duda JE, et al. Montreal cognitive assessment performance in patients with Parkinson's disease with “normal” global cognition according to Mini-Mental State Examination score. J Am Geriatr Soc 2009; 57: 304-308.
- 19 Hoops S, Nazem S, Siderowf A, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009; 73: 1738-1745.
- 20 Dalrymple-Alford J, MacAskill M, Nakas C, et al. The MoCA well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
- 21 Jurica P, Leitten C, Mattis S. Dementia Rating Scale-2: Professional manual. Lutz: Psychological Assessment Resources, 2001.
- 22 Brown GG, Rahill AA, Gorell JM, et al. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. J Geriatr Psychiatry Neurol 1999; 12: 180-188.
- 23 Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 2008; 23: 1546-1550.
- 24 Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimer's & Dementia 2013; 9: 529-537.
- 25 Bronnick K, Emre M, Lane R, Tekin S, Aarsland D. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurology Neurosurg Psychiatry 2007; 78: 1064-1068.
- 26 Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
- 27 Fahn S, Elton RL, UPDRS Program Members. Unified Parkinson's disease rating scale. In: S Fahn, CD Marsden, M Goldstein, DB Calne, editors. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987. p 153-163, 293–304.
- 28 Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: T Brink, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Haworth Press, 1986:165-173.
- 29 Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
- 30 IBM Corp. IBM SPSS Statistics for Macintosh, Version 22.0. Armonk, NY: Author, 2013.
- 31
Kolen MJ,
Brennan RL. Test Equating, Scaling, and Linking: Methods and Practices. New York, NY: Springer, 2004.
10.1007/978-1-4757-4310-4 Google Scholar
- 32 Fong TG, Fearing MA, Jones RN, et al. Telephone interview for cognitive status: Creating a crosswalk with the Mini-Mental State Examination. Alzheimer's & Dementia 2009; 5: 492-497.
- 33 Moses T, vonDavier A. An SAS Macro for Loglinear Smoothing: Applications and Implications. Montreal: American Educational Research Association, 2005.
- 34 Albano A. Equate: Observed-Score Linking and Equating. R package version 2.0-2. 2014.
- 35 Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. Mov Disord 2011; 26: 1814-1824.
- 36 Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
- 37 Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245.
- 38 Freitas S, Simões MR, Alves L, Santana I. Montreal Cognitive Assessment: influence of sociodemographic and health variables. Arch Clin Neuropsychol 2012; 27: 165-175.
- 39 O'Connor D, Pollitt P, Treasure F, Brook C, Reiss B. The influence of education, social class and sex on Mini-Mental State scores. Psychol Med 1989; 19: 771-776.
- 40 Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-1349.
- 41 Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170-1176.
- 42 Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord 2008; 23: 653-659.
- 43
Aarsland D,
Larsen J,
Karlsen K,
Lim N,
Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-874.
10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar
- 44 Vossius C, Larsen JP, Janvin C, Aarsland D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 2011; 26: 1541-1544.
- 45 Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, Vickrey BG. Development of quality of care indicators for Parkinson's disease. Mov Disord 2004; 19: 136-150.
- 46 American Academy of Neurology (AAN). Parkinson's disease physician performance measurement set. St. Paul, MN: American Academy of Neurology (AAN); 2009.
